Articles tagged with Drug Therapy
A new research project from Aarhus University found that test-tube children are generally as mentally healthy as naturally conceived children. However, children born to mothers who received hormone stimulation treatment for infertility have a small but increased risk of developing mental disorders such as autism or ADHD.
Israel's unique blend of medical innovation, universal accessibility and patient compliance leads to significant reduction in preventable blindness rates. The country's success in preventing avoidable blindness has emerged as a world leader, making it an attractive model for other nations.
A new treatment approach using MGN1703, a small DNA molecule that stimulates the immune system, has shown promise in prolonging progression-free survival in patients with metastatic colorectal cancer. The drug is designed to broadly activate all components of the innate immune system to destroy cancer cells.
A study found that biological tumor necrosis factor inhibitors did not significantly reduce work loss compared to conventional treatment in patients with early rheumatoid arthritis. Early and aggressive treatment can help reverse increasing work loss days, but the cost of infliximab outweighs its benefits.
The latest IST-3 results show that alteplase treatment significantly improves mobility, self-care, and overall quality of life in stroke survivors. At 18 months, patients treated with alteplase had a 28% greater odds of being alive and independent compared to those not receiving the drug.
A study found specific patterns of brain activity can indicate whether a patient will respond to medication or psychotherapy for depression. Low activity in the anterior insula region was associated with remission through CBT, while high activity was linked to improved response to medication.
Researchers at The Mount Sinai Medical Center found that commonly prescribed medications can either block or enhance beta-amyloid accumulation in the brain. Treatment with certain drugs has been shown to significantly reduce amyloid plaques and neurodegeneration in mice.
Researchers found that rapamycin improved cardiac function and reduced inflammation in aged mice, slowing down heart dysfunction. The study suggests potential benefits for humans with heart disease, as it is already FDA-approved for other indications.
A new software toolkit combines deformable anthropomorphic models with precision dosimetry to determine the most effective cancer-killing dose for every patient. This approach enables personalized radionuclide drug therapies, leading to improved outcomes and better survival rates.
Researchers at the University of Guelph have discovered a liver enzyme that protects cells from bilirubin damage, paving the way for new treatments for jaundice. The enzyme helps remove bilirubin and prevent liver cell death, offering hope for alternative therapies.
Researchers found that consistent bedtime within 45 minutes increases likelihood of using CPAP for at least four hours. Adults with inconsistent bedtimes are more likely to nonadhere to treatment, increasing odds by 3.2 times.
Theoretical mathematical models can help analyze viral dynamics in the early phase following exposure to HIV, providing insights into therapeutic and prevention strategies. The models suggest that reverse transcriptase inhibitors are more effective than protease inhibitors for PrEP, while fast initiation of treatment is crucial for PEP.
A new experimental iPhone application has been shown to transmit diagnostic heart images faster and with greater reliability than current methods. The app could help save lives by speeding treatment for STEMI, the deadliest type of heart attack.
IDIBELL has licensed a patent for a repositioned drug to treat X-linked adrenoleukodystrophy, a rare neurodegenerative disease. The patented product has shown promise in laboratory studies, but further research is needed before its application can be considered.
Researchers at the University of Illinois have developed a small molecule that breaks up protein-RNA clusters causing muscular dystrophy, offering hope for treatment. The compound targets only the repeating RNA sequence, increasing regulatory activity and breaking up disease-causing clusters.
The increasing cost of leukemia treatments in the US is leaving many patients under- or untreated due to unaffordable care. CML experts call for a long-term solution to manage treatment costs, balancing investments from various parties.
The European Society of Cardiology recommends catheter-based renal denervation for patients with resistant hypertension, indicating its potential in treating multiple cardiovascular diseases. The technique involves radiofrequency ablation to reset renal blood pressure regulation and reduce whole-body sympathetic nerve activity.
A retrospective study suggests that patients with lung cancer carrying specific HER2 mutations may experience tumor shrinkage and delayed disease progression when treated with anti-HER2 drugs. The study found 1.7% of NSCLC patients in Europe had these rare mutations, which can lead to continuous activation of the HER2 protein.
Researchers discovered that nalmefene significantly reduces alcohol consumption and improves patients' clinical status and liver enzymes. The medication is well-tolerated with mild to moderate side effects.
Researchers have developed nanoparticles that improve siRNA delivery, enabling more efficient silencing of specific genes. The approach shows promise in addressing the challenge of targeted delivery for gene therapies.
Researchers at the University of Manchester have made a breakthrough in developing an effective treatment for neurodegenerative diseases. They identified the molecular structure of the enzyme kynurenine 3-monooxygense (KMO) and discovered a compound that can inhibit its activity.
A study published in Diabetologia found that only 10% of diabetes trials focus on prevention or behavioral therapies. Most trials are small to medium-sized and prioritize drug treatments over preventive measures. The analysis highlights the need for more research addressing the needs of diverse populations affected by diabetes.
Researchers developed biodegradable nanoparticles that deliver inflammation-resolving drugs to sites of tissue injury, promoting clearance of pathogens or damaged tissue and restoring normal state. The treatment has potential for treating conditions like atherosclerosis and neurodegenerative diseases.
Researchers are developing tiny sensory implants that can measure vital tumor factors, enabling doctors to target radiotherapy and chemotherapy for more effective treatment. The devices aim to personalize therapy based on individual patient responses, improving recovery chances.
Researchers have developed an algorithm that can explain how traditional medicinal compounds work in the body, bridging the gap between Western and traditional medicine. This breakthrough may lead to more effective treatments for various diseases.
Researchers have mapped tapeworm genomes to identify potential drug targets using existing drugs, which could lead to faster and more effective treatments. The discovery has significant implications for the development of urgently needed therapies for these devastating diseases.
Researchers at Mount Sinai are studying spasmodic dysphonia, a neurological disorder characterized by vocal cord spasms. The team aims to identify new drug targets and diagnostic biomarkers using advanced neuroimaging methodologies.
A new study found that adrenocorticotropic hormone (ACTH) may be effective in treating people with breakthrough multiple sclerosis. Participants who received ACTH had fewer relapses and no psychiatric side effects, compared to those receiving methylprednisolone.
The European League Against Rheumatism recommends immediate use of synthetic DMARDs after diagnosis, but they are expensive. The survey found that 26 countries cannot afford biological DMARDs, excluding 320 million people from treatment.
Researchers identified a molecule called lipoxin A4 that plays a crucial role in resolving airway inflammation in asthma. This discovery provides new direction for developing next-generation asthma therapies to decrease chronic inflammation.
Researchers at Case Western Reserve University have validated a questionnaire to assess youth participation in Alcoholics Anonymous (AA)-related helping activities. The Service to Others in Sobriety (SOS) questionnaire shows promise in identifying youths at risk of relapse and promoting recovery.
A pilot study shows that qigong therapy significantly reduced cocaine cravings and depression symptoms in individuals undergoing residential substance abuse treatment. This promising treatment approach may have profound consequences in drug rehabilitation programs.
A preclinical study uses ultrasonic molecular imaging and Dynamic Contrast Enhanced-Perfusion Imaging to measure response to pancreatic cancer therapy. The study reveals that these new technologies can detect molecular signs of tumor response after just 2 days, improving the early identification of therapeutic response.
Patients with spinal stenosis who receive steroid injections show less improvement in pain and physical functioning, regardless of whether they undergo surgery. The study suggests that ESI may cause worsening of spinal narrowing or nerve impingement, leading to more complicated surgeries.
A new enzyme therapy has significantly delayed the onset and progression of symptoms in dogs with Batten disease, a rare genetic disorder affecting children. The treatment, developed by MU and BioMarin researchers, replaces the deficient enzyme and is administered into the spinal fluid, slowing brain degeneration and extending survival.
A recent study published in Cell Reports found that sunitinib, an anticancer drug, does not cause lingering risks for patients after their treatment ends. The research suggests that sunitinib works by slowing tumor growth and prolonging survival during treatment, without altering tumor biology after the drug is stopped.
A pair of commentaries highlight a public health debate surrounding CDC treatment guidelines for exposed individuals during the 2012 fungal meningitis outbreak. The American Society for Microbiology has published two commentaries questioning and defending the CDC's recommendations.
Researchers from Arunachal Pradesh and the Research Institute of World's Ancient Traditions Cultures and Heritage successfully isolated dormant TB bacteria from CD271+ stem cells in bone marrow. The study provides evidence that TB bacteria hide in these stem cells to escape drug treatment, making it difficult to eradicate the disease.
A new enzyme treatment has been developed to neutralize the effects of lethal chemicals responsible for thousands of deaths each year. The treatment, known as a bioscavenger, was found to protect mice against nerve agents and showed no lasting effects.
A new study from the University of Pennsylvania School of Medicine found that black and Hispanic patients are less likely to complete substance abuse treatment programs compared to white patients. The study suggests that socioeconomic factors, such as unemployment and housing instability, contribute to these disparities.
A new NIH-funded study shows that inexpensive education efforts can increase safe use of clot-busting drug tPA at local hospitals, improving stroke care. Community hospitals across Michigan saw a significant improvement in tPA use rates after receiving educational support and round-the-clock treatment assistance.
A systematic review found that children and teenagers diagnosed with PTSD showed signs of improvement up to three months following treatment. Psychological therapies, particularly cognitive behavioural therapy, have been shown to be effective in treating post-traumatic stress disorder in children, reducing anxiety and depression symptoms.
A groundbreaking clinical trial reveals that women with estrogen receptor-positive breast cancer who take tamoxifen for 10 years have a lower risk of recurrence and mortality rate compared to those taking the drug for 5 years. This new finding may prompt patients to reconsider their treatment options, particularly premenopausal women.
A new targeted drug, regorafenib, has demonstrated its ability to control metastatic gastrointestinal stromal tumor (GIST) in patients who have become resistant to all existing therapies. The treatment improved disease control and survival rates for nearly four months longer than placebo.
Researchers identified potent antiepileptic fatty acids in the ketogenic diet, which could lead to a new pill for controlling seizures. The discovery aims to replace the high-fat, low-carbohydrate diet with a safer treatment option.
Researchers explored the benefits of adding radionuclide therapy to cancer treatment regimens for patients with advanced disease. Studies found improved tumor control rates and longer patient survival without significant side effects, suggesting a potential paradigm shift in cancer control.
A new study found that adding Gemtuzumab Ozogamicin to chemotherapy treatment improved the effectiveness of cancer treatment without increasing side effects in older AML patients. The results show a 22% lower risk of relapse and a 13% lower mortality rate compared to standard treatment.
Researchers at MIT developed a microfluidic device that captures circulating tumor cells using DNA 'tentacles' inspired by jellyfish. The device increases flow rates 10 times higher than existing ones, enabling rapid processing of blood samples and potential monitoring of cancer patients.
A new study by the American Psychological Association found that about half of addiction counselors in the US now find moderate drug use acceptable as an intermediate goal, while one-third consider it acceptable as a final goal. However, for clients with severe dependence, limits on consumption are still widely rejected.
A new study published in CNS Drugs found that a single dose of etanercept can rapidly improve chronic neurological dysfunction caused by stroke or traumatic brain injury, even years after the event. The observational study involved 629 patients and documented positive effects on motor impairment, spasticity, cognition, and more.
Cardiac arrhythmias affect over one million people in the UK, with a growing gap between technology advancements and biological understanding. The Lancet series explores new treatments and future directions for arrhythmia management.
Researchers are developing new medications and oral immunotherapy to treat food allergies, such as egg and peanut allergies. These treatments show promise in reducing emergency room visits and healthcare costs associated with food allergies.
A new study found a connection between Alzheimer's disease and the activity level of eIF2alpha protein. Researchers believe altering this protein via drug therapy could lead to a treatment for the incurable disease.
Researchers at Washington University School of Medicine applied Toyota's lean manufacturing process to improve stroke treatment times, reducing average door-to-needle time from 58 to 37 minutes. The new protocol eliminated inefficient steps and allowed for simultaneous patient care tasks.
Researchers have developed a novel compound from vegetable sources that demonstrates superior anticancer activities, particularly against triple-negative breast cancer. The orally active compounds could offer safer and more effective treatment options for patients.
Dr. Bowen Chung is conducting two studies to improve mental health care for troubled youths and adolescents, focusing on family therapy and resiliency classes. The first study will test the effectiveness of family-focused therapy in improving treatment outcomes for psychotic and bipolar adolescents.
A new study comparing oral medication and Botox injections for treating urge urinary incontinence in women found that both treatments were effective in reducing symptoms, but with varying side effects. The study, which involved nearly 250 women, showed that Botox was more likely to completely eliminate urinary leakage, while oral medic...
Researchers have discovered a new PET imaging agent that can predict the early response to treatment for head and neck cancer patients. The agent, 3'-deoxy-3'F-18-fluorothymidine (18-F-FLT), showed high accuracy in detecting therapeutic responses and identifying patients needing close follow-up.
Researchers found that administering immunotherapy for three years can achieve long-term control of allergic asthma and reduce symptoms. After three years, 50 percent of children with dust mite-induced asthma experienced remission, needing reduced or no controller medications.
Researchers have found that one year of treatment with trastuzumab is as good as two years of treatment, improving outcomes and reducing the risk of disease recurrence. This conclusion comes from the HERA trial, which involved over 5100 women with early HER2-positive breast cancer.